Sitafloxacin (INN; also called DU-6859a) is a fluoroquinolone antibiotic[1] that shows promise in the treatment of Buruli ulcer.

The molecule was identified by Daiichi Sankyo Co., which brought ofloxacin and levofloxacin to the market.

Sitafloxacin is currently marketed in Japan by Daiichi Sankyo under the tradename Gracevit.

[citation needed] This systemic antibiotic-related article is a stub.

You can help Wikipedia by expanding it.